Immix Biopharma, Inc. (IMMX)
After hours:
| Previous Close | 2.1000 |
| Open | 2.0800 |
| Bid | 2.0900 x 100 |
| Ask | 2.2100 x 100 |
| Day's Range | 2.0500 - 2.2500 |
| 52 Week Range | 1.4000 - 7.7500 |
| Volume | |
| Avg. Volume | 255,825 |
| Market Cap | 56.224M |
| Beta (5Y Monthly) | 0.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8900 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
GlobeNewswireImmix Biopharma on Track to Dose NXC-201 Patients in United States
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No change in patient enrollment timing LOS ANGELES, April 18, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today
- GlobeNewswire
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 27th
- GlobeNewswire
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial. “We are looking forward to this important multi-site clinical trial with NXC-201 CAR-T
